Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Martijn W.J. Stommel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4257-5254; OpenAlex author ID A5060176696, A5113435178, A5123529795. Sources: ClinicalTrials.gov.

Their work

Papers
75 (first author 1, last author 6)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
185
Papers, trials and grants by year

2019: 1 paper · 2020: 4 papers · 2021: 7 papers · 2022: 7 papers · 2023: 7 papers, 1 trial · 2024: 16 papers · 2025: 18 papers · 2026: 15 papers

Papers 50 of 75

  1. Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. Co-author DOI 10.1001/jamanetworkopen.2026.3861↗
  2. Transcriptome-Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant T… Co-author DOI 10.1002/ijc.70519↗
  3. Quantitative CT Perfusion as a prognostic biomarker for chemotherapy response in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00261-026-05420-5↗
  4. The impact of age on quality of life, 90-day mortality, adjuvant chemotherapy, and survival after treatment for localized pancreatic cancer: A nationwide analy… Co-author DOI 10.1016/j.ejca.2026.116822↗
  5. Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dut… Co-author DOI 10.1016/j.ejca.2026.117776↗
  6. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. Co-author DOI 10.1016/j.ejso.2025.111165↗
  7. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  8. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  9. A paradox in the quality of care in centralization of pancreatic cancer surgery. First author DOI 10.1093/bjs/znag092↗
  10. Gastrointestinal symptoms and health-related quality of life before and after pancreatectomy for pancreatic cancer (GO-PANC): longitudinal nationwide study. Co-author DOI 10.1093/bjs/znag122↗
  11. Continuity of care experienced by patients diagnosed with pancreatic cancer: nationwide multicentre study. Last author DOI 10.1093/bjsopen/zrag033↗
  12. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  13. Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18639-1↗
  14. ASO Visual Abstract: Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18791-8↗
  15. The Value of Stereotactic Radiotherapy After FOLFIRINOX in Patients with Pancreatic Cancer with Vascular Contact-A Nationwide, Retrospective Cohort Study. Co-author DOI 10.3390/cancers18040700↗
  16. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  17. Survival scenarios of patients with localized and metastatic pancreatic adenocarcinoma: A population-based study. Co-author DOI 10.1002/ijc.35267↗
  18. Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characte… Co-author DOI 10.1002/path.6437↗
  19. Longitudinal health-related quality of life in patients with pancreatic cancer stratified by treatment: a nationwide cohort study. Co-author DOI 10.1016/j.eclinm.2024.103068↗
  20. Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: Nationwide population-based … Co-author DOI 10.1016/j.ejca.2025.115385↗
  21. Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort. Co-author DOI 10.1016/j.pan.2025.03.011↗
  22. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  23. Resectability stages of pancreatic cancer: nationwide reference. Co-author DOI 10.1093/bjs/znaf120↗
  24. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  25. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  26. Evaluation of Short and Long-term Outcomes After Resection in Patients With Locally Advanced Versus (Borderline) Resectable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006289↗
  27. Perineural Invasion is an Important Prognostic Factor in Patients With Radically Resected (R0) and Node-negative (pN0) Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006320↗
  28. Routine Imaging After Resection of Pancreatic Ductal Adenocarcinoma: Nationwide Utilization and Survival Analysis. Co-author DOI 10.1097/sla.0000000000006772↗
  29. Intratumoral Holmium-166 Microsphere Injection in Patients with Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Center, Single-Arm, Open-Label Feasibil… Co-author DOI 10.1159/000545246↗
  30. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  31. How to Improve Pancreatic Cancer Network Care Using a Human-Centered Design Sprint. Last author DOI 10.2196/55598↗
  32. Development of an Intratumoral Holmium Microsphere Injection Method in Ex Vivo Human Pancreatic Ductal Adenocarcinoma: A Preclinical Feasibility Study. Co-author DOI 10.3390/cancers17061028↗
  33. Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study. Co-author DOI 10.6004/jnccn.2024.7091↗
  34. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  35. Preoperative chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula after pancreatoduodenectomy for pancrea… Co-author DOI 10.1016/j.surg.2024.01.029↗
  36. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. Co-author DOI 10.1093/jnci/djae070↗
  37. Predicting Long-term Disease-free Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Cohort Study. Co-author DOI 10.1097/sla.0000000000006004↗
  38. Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients With Locally Advanced Pancreatic Cancer: A Nationwide Multicenter Study. Co-author DOI 10.1097/sla.0000000000006021↗
  39. Poor Prognostic Factors in Long-Term Survivors of Resected Pancreatic Ductal Adenocarcinoma: An International, Multicenter Cohort Study. Co-author DOI 10.1097/sla.0000000000006539↗
  40. Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an i… Co-author DOI 10.1186/s13063-024-08223-5↗
  41. Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): prot… Co-author DOI 10.1186/s13063-024-08295-3↗
  42. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Co-author DOI 10.1245/s10434-023-14650-6↗
  43. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone f… Co-author DOI 10.1245/s10434-023-14704-9↗
  44. The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis. Co-author DOI 10.1245/s10434-024-15070-w↗
  45. Prediction of Isolated Local Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Study. Co-author DOI 10.1245/s10434-024-15664-4↗
  46. Surgical Outcome After Distal Pancreatectomy With and Without Portomesenteric Venous Resection in Patients with Pancreatic Adenocarcinoma: A Transatlantic Eval… Co-author DOI 10.1245/s10434-024-15932-3↗
  47. ASO Author Reflections: Distal Pancreatectomy With and Without Portomesenteric Venous Resection for Pancreatic Adenocarcinoma: A Transatlantic Evaluation of Pa… Co-author DOI 10.1245/s10434-024-16021-1↗
  48. Limited Role of the Apparent Diffusion Coefficient (ADC) for Tumor Grade and Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/diagnostics14060573↗
  49. The Difficulty of Detecting Occult Metastases in Patients with Potentially Resectable Pancreatic Cancer: Development and External Validation of a Preoperative … Co-author DOI 10.3390/jcm13061679↗
  50. Nationwide evaluation of pancreatic cancer networks ten years after the centralization of pancreatic surgery. Last author DOI 10.1016/j.hpb.2023.07.904↗

Trials 1

  1. The Effectiveness of Adding Braun Anastomosis to Standard Child Reconstruction After Pancreatoduodenectomy Principal investigator NCT05709197↗

Closest collaborators

The 25 strongest of 185 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 53 shared papers, 2019–2026 · strength 7.97
  2. Ignace H. J. T. de Hingh · 46 shared papers, 2020–2026 · strength 6.74
  3. Izaak Quintus Molenaar · 45 shared papers, 2019–2026 · strength 6.46
  4. Hjalmar C. van Santvoort · 44 shared papers, 2019–2026 · strength 6.38
  5. Vincent Erwin de Meijer · 39 shared papers, 2020–2026 · strength 5.93
  6. Lois A. Daamen · 33 shared papers, 2019–2026 · strength 5.14
  7. Bas Groot Koerkamp · 35 shared papers, 2019–2026 · strength 5.04
  8. Sebastiaan Festen · 29 shared papers, 2021–2026 · strength 4.22
  9. Bert A. Bonsing · 26 shared papers, 2020–2026 · strength 3.78
  10. Johanna W. Wilmink · 24 shared papers, 2019–2026 · strength 3.76
  11. Judith de Vos‐Geelen · 22 shared papers, 2020–2026 · strength 3.51
  12. Geert Kazemier M · 22 shared papers, 2020–2026 · strength 3.25
  13. Casper H.J. van Eijck · 20 shared papers, 2020–2026 · strength 2.97
  14. Hanneke W.M. van Laarhoven · 17 shared papers, 2019–2026 · strength 2.92
  15. Gijs A. Patijn · 18 shared papers, 2021–2026 · strength 2.54
  16. Robert C. Verdonk · 15 shared papers, 2022–2026 · strength 2.36
  17. Vincent B. Nieuwenhuijs · 17 shared papers, 2020–2026 · strength 2.30
  18. Iris W.J.M. van Goor · 14 shared papers, 2021–2026 · strength 2.30
  19. Thijs J. Schouten · 15 shared papers, 2021–2026 · strength 2.27
  20. Lodewijk A.A. Brosens · 14 shared papers, 2021–2026 · strength 2.22
  21. Vincent P. Groot · 14 shared papers, 2019–2026 · strength 2.07
  22. Lydia G. van der Geest · 11 shared papers, 2020–2026 · strength 1.96
  23. Paul C. M. Andel · 11 shared papers, 2024–2026 · strength 1.91
  24. Marjolein Y.V. Homs · 11 shared papers, 2020–2026 · strength 1.83
  25. Jana S. Hopstaken · 6 shared papers, 2022–2026 · strength 1.59

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.